期刊文献+

HNK盐酸盐药物的血脑屏障通透性试验

Experimental Design of Blood-Brain Barrier Permeability of Hydroxynorketamine Hydrochloride
下载PDF
导出
摘要 以HNK盐酸盐药物为试验药品,采用尾静脉注射和灌胃两种给药方式对试验动物直接给药,并在规定的8个时间点收集血液和大脑,将样品进行一系列的处理,在液相质谱仪中进行检测,结果显示:尾静脉给药条件下,血和脑的药物浓度在1 h后达到最低检测限,血脑屏障通透率为1.61;灌胃给药条件下血的药物溶解度在4 h后达到最低检测限,脑的药物溶解度在2 h后达到最低检测限,血脑屏障通透率为0.53。结论显示,这种HNK盐酸盐药物可以透过血脑屏障进入大脑并作用于大脑,且尾静脉给药比灌胃给药的效果更快更好。 Tail intravenous injection and intragastric administration of drug were conducted on ICR mice;after that blood and brain samples were collected at the specified eight time points.Samples were detected by liquid chromatography-mass spectrometry after a series of processing.The results showed that in the situation of intravenous injection,the concentration of HNK hydrochloride drug in blood and brain was lower than minimum detection limit after one hour and the brain permeability ratio was 1.61.In the situation of intragastric administration,the concentration of drug in blood was lower than minimum detection limit after four hours and the concentration of drug in brain was lower than minimum detection limit after two hours and the brain permeability ratio was 0.53.The HNK hydrochloride drug could pass through blood brain barrier and the effect of drug by intravenous injection was better than that by intragastric administration.
作者 严丹红 YAN Danhong(Suzhou Chien-shiung Institute of Technology,Taicang 215411,China)
出处 《江苏工程职业技术学院学报》 2017年第4期6-9,共4页 Journal of Jiangsu College of Engineering and Technology
基金 江苏省自然科学基金青年基金项目"叶酸受体及肿瘤血管内皮细胞特异性受体介导的双靶向载药缓释微球的制备及评价"(编号BK20130385)
关键词 血脑屏障 小鼠 液相质谱 最低检测限 药物溶解度 blood brain barrier ICR mice liquid chromatography-mass spectrometry minimum detec.tion limit drug concentration
  • 相关文献

参考文献3

二级参考文献258

  • 1Gayatri P,Suneel PR,Sinha PK,et al.Evaluation of propofol ketamine anesthesia for children undergoing cardiac catheterization procedures[J].J Interv Cardiol,2007,35(4):634-648.
  • 2Münte 8,Munte TF,Kuche H,et al.General anesthesia for interventional neuroradiology:propofol versus isoflurane[J].J Clin Anesth,2001,65(45):1598-1620.
  • 3Cavallero S,Gonzalez GE.Atrial natriuretic peptide behaviour and myocyte hypertrophic profile in combined pressure and volume induced cardiac hypertrophy[J].J Hypertens,2007,25(7):358-398.
  • 4Orser BA,Pennefather PS,Macdonald JF.Multiple mechanisms of ketamine block ade of NMethylDAspartate receptors[J].Anesthesiology,2007,86(10):579-608.
  • 5Akin A,Esmaoglu A,Guler G.Propofol and propofol ketamine in pediatric patients undergoing cardiac catheterization[J].Pediatr Cardiol,2005,16(7):553-557.
  • 6黄生民 刘嘉亮.口服氯胺酮在烧伤整形患儿换药的应用.临床麻醉学杂志,2008,5(11):37-39.
  • 7赵崇璧 王森宇.氯胺酮与安定在现代临床医学麻醉处理中的应用与研究进展.中国比较医学杂志,2005,8(5):17-19.
  • 8Salameh TS, Banks WA. Delivery of therapeutic peptides and proteins to the CNS [J].Adv Pharmacol, 2014,71:277-299.
  • 9Doolittle ND, Muldoon LL, Culp AY, et al. Delivery of chemotherapeutics across the blood-brain barrier: Challenges and advances [J].Adv Pharmacol, 2014,71:203-243.
  • 10Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications [J].Neurobiol Dis, 2004,16(1):1-13.

共引文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部